Arising Health · Podcast
The Arising Signal.
The Arising’s reporting on longevity, medicine, and the business of health, in audio.
Subscribe via RSS ↗
Latest episode
The difference between knowing and knowing what to do
Six stories from the November 18 edition ask what a finding actually changes: a blood test that can guide treatment for some advanced breast cancers, a blood marker that helps estimate cognitive risk, a trial of eating windows and liver fat, supervised exercise after 60, plaque-measuring software, and a Medicare pilot that ties payment to outcomes. This episode uses an AI-generated version of John Griffin’s voice.
Earlier episodes
What a number can tell you, and what it can’t
John Griffin revisits what the November 16 reporting can and can’t tell us: postwar sugar rationing and biological-age estimates, shingles vaccination and dementia research, measuring perimenopause symptoms, protein and health, and a once-weekly HIV treatment trial. This episode uses an AI-generated version of John Griffin’s voice.
Hormone therapy and heart risk
Sarah and Michael open with a study of hormone therapy in midlife. They also discuss mitochondrial replacement in fertility clinics, a liver fibrosis trial, and investment in senior housing.
What do slow waves during REM sleep tell us?
Sleep researchers are finding unexpected patterns in REM sleep as people age. Also in this edition: a heart valve designed for growing children, biological age estimates, and changes in Medicare Advantage.
Remission in type 2 diabetes
The hosts discuss the RESET trial in younger adults with type 2 diabetes, a small trial in liver fibrosis, and changes to estrogen patch labeling.
A pill for sleep apnea?
An investigational pill for sleep apnea leads this edition. Sarah and Michael also cover a gene-editing trial, blood pressure medication, and what happens after people stop taking tirzepatide.
An early glaucoma trial
What can researchers learn from the first three patients in a reprogramming trial? The hosts also discuss a melanoma vaccine, bone density during weight loss, and an Alzheimer’s trial.